hearing

VRT-534 is a compound that selectively targets connexin 26 (Cx26), demonstrating dose-responsive binding to both wild-type (WT) Cx26 and the mutant Cx26 K188N, with EC50 values of 19 μM and 5 μM, respectively. It has potential applications in research concerning hearing impairment [1].

NMB-1, a conopeptide analogue, selectively inhibits sustained mechanically activated currents in sensory neurons with an IC50 of 1 μM, attenuating mechanical pain. It is utilized in research pertaining to hearing and pressure-evoked pain [1] [2].

(R)-Azasetron besylate (SENS-401), an orally active calcineurin inhibitor, has been shown to mitigate cisplatin-induced hearing loss and cochlear damage [1][2].

Adenosine amine congener (ADAC) (ADAC) is an agonist of selective A1 adenosine receptor,.

KX1-004, a potential protective drug for NIHL, is an effective small molecule inhibitor of Src-PTK.

NK1 Receptor Antagonist 2, a compound targeting the NK1 receptor, holds potential for tinnitus and hearing loss research.

Sodium thiosulfate (Pentahydrate) is an antioxidant and antifungal. Sodium thiosulfate protects against cisplatin-induced hearing loss in children and is not associated with serious adverse events attributed to its use[3]. The addition of sodium thiosulfate, administered 6 hours after cisplatin chemotherapy, resulted in a lower incidence of cisplatin-induced hearing loss among children with standard-risk hepatoblastoma, without jeopardizing overall or event-free survival[4]. Calciphylaxis is a potentially fatal disorder of abnormal calcium deposition. Treatment is multifaceted, and improved outcomes have been demonstrated with intravenous sodium thiosulfate; however, the use of this medication can be limited by its adverse effects[5]. TST (topical sodium thiosulfate) appears to be a relatively well-tolerated adjuvant treatment for CC(calcinosis cutis)[6]. The combined treatment of sodium thiosulfate, pamidronate and calcitomimetics has been effective and safe for the treatment of calciphylaxis, inducing complete remission[7].

Orc-13661 (BNP-13661) is a potent and well-tolerated oral active protective agent for the prevention of aminogrogycoside-induced hearing loss.

BF844 is a chemical compound that demonstrates the ability to mitigate hearing loss in individuals with Usher Syndrome Type III (USH3) caused by the CLRN1 mutation (specifically N48K). One of its mechanisms of action is the transportation of CLRN1 N48K to the plasma membrane. In vivo studies have shown that BF844 significantly preserves hearing [1].

Dieckol, a rhizomycin found in some brown algae species, has antimicrobial, anticancer, antioxidant, antiaging, antidiabetic, and neuroprotective effects, ameliorates acute hearing loss, and inhibits cell proliferation through cell cycle arrest in human tracheal fibroblasts via Hs680.Tr.